New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
11:21 EDTARIA, WPX, VOLC, PVTB, PANW, IFNNY, GILD, FRX, CBST, CELG, BIIB, AMGN, ALXN, ABMD, ZLCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Guggenheim... Abiomed (ABMD) initiated with a Market Perform at Raymond James... Alexion (ALXN) initiated with a Buy at Guggenheim... Amgen (AMGN) initiated with a Neutral at Guggenheim... Biogen (BIIB) initiated with a Neutral at Guggenheim... Celgene (CELG) initiated with a Buy at Guggenheim... Cubist (CBST) initiated with a Neutral at Mizuho... Forest Labs (FRX) initiated with a Buy at Mizuho... Gilead (GILD) initiated with a Buy at Guggenheim... Infineon (IFNNY) initiated with an Outperform at Bernstein... Palo Alto (PANW) initiated with a Neutral at BofA/Merrill... PrivateBancorp (PVTB) initiated with a Market Perform at Wells Fargo... Volcano (VOLC) initiated with an Outperform at Raymond James... WPX Energy (WPX) initiated with a Hold at Deutsche Bank... Zale (ZLC) initiated with a Buy at Citigroup.
News For ARIA;ABMD;ALXN;AMGN;BIIB;CELG;CBST;FRX;GILD;IFNNY;PANW;PVTB;VOLC;WPX;ZLC From The Last 14 Days
Check below for free stories on ARIA;ABMD;ALXN;AMGN;BIIB;CELG;CBST;FRX;GILD;IFNNY;PANW;PVTB;VOLC;WPX;ZLC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 21, 2014
06:57 EDTIFNNYInfineon mulled 'bunch' of possible takeovers before making pick, Reuters says
Subscribe for More Information
August 20, 2014
12:45 EDTIFNNYInfineon acquires International Rectifier in $3B deal
Subscribe for More Information
12:37 EDTIFNNYOn The Fly: Midday Wrap
Subscribe for More Information
12:26 EDTIFNNYInternational Rectifier volatility collapses on Infineonon acquiring for $3B
Subscribe for More Information
12:15 EDTIFNNYInternational Rectifier discontinues share repurchase program
International Rectifier (IRF) entered into a definitive agreement with Infineon Technologies (IFNNY) under which Infineon has agreed to acquire International Rectifier for $40 per share in an all-cash transaction valued at approximately $3B. In anticipation of this transaction which is expected to close late in the calendar year 2014 or early in the calendar year 2015 subject to regulatory approval, International Rectifier will not conduct a fourth quarter results conference call nor issue financial guidance for the upcoming quarter. International Rectifier is also discontinuing its share repurchase program.
12:06 EDTIFNNYInfineon to acquire International Rectifier for $40 per share in cash
Subscribe for More Information
12:03 EDTIFNNYInfineon to acquire International Rectifier for $40 per share in cash
Subscribe for More Information
11:43 EDTIFNNYSpansion, Semtech off highs after International Rectifier halt
Subscribe for More Information
10:41 EDTIFNNYInfineon not buying Fairchild or Fairchild, Reuters reports
A source said Infineon (IFNNY) is not buying Fairchild (FCS) or Freescale (FSL) and declined to comment on other potential takeover candidates, Reuters reports. Infineon is seeking to acquire a U.S.-based semiconductor company for about $2B, Reuters and Bloomberg reported today, citing sources. Semtech (SMTC) was listed by Bloomberg as a potential target for Infineon along with Fairchild and Freescale. Reference Link
09:07 EDTIFNNYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PetSmart (PETM), up 2,1%... Staples (SPLS), up 2%... E-House (EJ), up 2.5%. HIGHER: Fairchild (FCS), up 4% after Bloomberg says Infineon (IFNNY) is near a deal to buy a U.S. semiconductor company for $2B... Amicus Therapeutics (FOLD), up 18.4% after reporting positive Phase 3 data from the Fabry study. DOWN AFTER EARNINGS: Lowe's (LOW), down 3%... Tarena (TEDU), down 9%... Leju (LEJU), down 4.2%... JA Solar (JASO), down 5%. LOWER: Hertz (HTZ), down 12.7% after downgraded at JPMorgan and Deutsche Bank following the company's decision to withdraw its FY14 guidance... NovaBay (NBY), down 35.2% after primary, secondary endpoints were not met in its NVC-422 study... RGS Energy (RGSE), down 14.9% after downgraded at Roth Capital following Q2 earnings results.
08:43 EDTIFNNYInfineon 'not commenting on rumors,' seeking acquisitions, Reuters reports
Subscribe for More Information
08:42 EDTIFNNYInfineon nears deal to buy U.S. semi company for $2B, Bloomberg reports
Subscribe for More Information
08:02 EDTCELGBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
08:02 EDTPANWPalo Alto expands global distribution agreement with Westcon Group
Subscribe for More Information
07:25 EDTIFNNYFairchild jumps 5% after Bloomberg says Infineon near deal
Shares of Fairchild Semiconductor (FCS) are rallying 5% in pre-market trading to $16.75 after Bloomberg reported that Infineon (IFNNY) is near a deal to buy a U.S. chipmaker for around $2B. Bloomberg listed Fairchild, Semtech (SMTC) and Freescale (FSL) as potential takeover targets in the semiconductor space. The news agency said Infineon could announce an acquisition as early as today.
07:01 EDTIFNNYInfineon near deal to buy U.S. semi company for $2B, Bloomberg says
Subscribe for More Information
August 19, 2014
16:00 EDTGILDOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
09:38 EDTCELG, GILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
05:11 EDTAMGNGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use